J Korean Med Assoc.  2017 Feb;60(2):156-163. 10.5124/jkma.2017.60.2.156.

Pharmacologic treatment of rheumatoid arthritis

• Cho SK
• Bae SC

• KMID: 2368926
• DOI: http://doi.org/10.5124/jkma.2017.60.2.156

Abstract

Rheumatoid arthritis (RA) is a systemic inflammatory disease that affects the joints. This chronic inflammatory condition causes joint destruction and functional disability, and reduces the quality of life of patients. Therefore, the aims of RA treatment are to control a patient's symptoms by decreasing the inflammation, to prevent joint damage, and to maintain the patient's quality of life while minimizing the progress of the disease. In recent years, the early initiation of disease-modifying anti-rheumatic drugs (DMARDs) has been emphasized because a window of opportunity is thought to exist in early RA, when the disease is more responsive to treatment. Recently, the treat-to-target strategy for RA treatment has also been suggested. This strategy involves setting a goal such as remission or low disease state, implementing strict monitoring, and switching the medication regimen promptly as needed. Currently, several DMARDs are available to manage RA. DMARDs form two major classes: synthetic chemical compounds (sDMARDs) and biological agents (bDMARDs), which target specific pro-inflammatory cytokines to prevent inflammation. This review summarizes the effectiveness and safety of the current DMARDs available for RA treatment. Tumor necrosis factor inhibitors, T cell costimulation inhibitor, an anti-B cell agent, and the interleukin 6 receptor-blocking monoclonal antibody are classified as bDMARDs. Tofacitinib, a new sDMARD specifically designed to target janus kinases, is also discussed in this article.

Keyword

Arthritis, rheumatoid; Drug therapy; Antirheumatic agents

MeSH Terms

Antirheumatic Agents
Arthritis, Rheumatoid*
Biological Factors
Cytokines
Drug Therapy
Humans
Inflammation
Interleukin-6
Janus Kinases
Joints
Quality of Life
Tumor Necrosis Factor-alpha
Antirheumatic Agents
Biological Factors
Cytokines
Interleukin-6
Janus Kinases
Tumor Necrosis Factor-alpha

Reference

1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376:1094–1108.

2. Tiippana-Kinnunen T, Kautiainen H, Paimela L, Leirisalo-Repo M. Co-morbidities in Finnish patients with rheumatoid arthritis: 15-year follow-up. Scand J Rheumatol. 2013; 42:451–456.

3. Sung YK, Cho SK, Choi CB, Bae SC. Prevalence and incidence of rheumatoid arthritis in South Korea. Rheumatol Int. 2013; 33:1525–1532.

4. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73:492–509.

5. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016; 68:1–26.

6. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compan MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75:3–15.

7. Firestein GS, Kelley WN. Kelley's textbook of rheumatology. 9th ed. Philadelphia: Elsevier;2013.

8. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Rheumatology. 5th ed. Philadelphia: Mosby;2010.

9. Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J. Harrison's principle of internal medicine. 19th ed. New York: McGraw-Hill Education;2015.

10. Cecil RL, Goldman L, Schafer AI. Goldman's cecil medicine. 24th ed. Philadelphia: Elsevier;2012.

11. Klippel JH. Primer on the rheumatic diseases. 13th ed. New York: Springer;2008.

12. Lee WS, Lee SI, Lee MS, Kim SI, Lee SS, Yoo WH. Efficacy and safety of low-dose tacrolimus for active rheumatoid arthritis with an inadequate response to methotrexate. Korean J Intern Med. 2016; 31:779–787.

13. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011; 118:415–422.

14. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016; 123:1386–1394.

15. Hong MJ, Yoo WH. Biologic agents in rheumatic diseases. Korean J Med. 2012; 82:549–561.

16. Kim J, Song YW. Medical treatment of rheumatoid arthritis (II): current biologic agents and newly developing drugs. J Korean Med Assoc. 2010; 53:880–888.

17. Sung YK, Cho SK, Kim D, Won S, Choi CB, Bang SY, Hong SJ, Kim HA, Koh EM, Lee HS, Suh CH, Yoo DH, Bae SC. Characteristics and outcomes of rheumatoid arthritis Pa-tients who started biosimilar infliximab. Rheumatol Int. In press.

18. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007; 34:706–711.

19. Joint Committee for the Revision of Korean Guidelines for Tuberculosis. Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 1st ed. Cheongju: Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention;2011.

20. Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M;. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther. 2015; 17:74.

21. Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. 2016; 31:210–218.

22. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012; 64:617–629.

23. Lee EB. Small molecule inhibitors in rheumatoid arthritis. J Rheum Dis. 2012; 19:118–124.

24. Kim JW, Choi IA, Lee EY, Song YW, Lee EB. Tofacitinib prevents radiographic progression in rheumatoid arthritis. J Korean Med Sci. 2013; 28:1134–1138.

25. Sung YK, Cho SK, Kim D, Choi CB, Won S, Bang SY, Cha HS, Choe JY, Chung WT, Hong SJ, Jun JB, Kim HA, Kim J, Kim SK, Kim TH, Lee HS, Lee J, Lee J, Lee SS, Lee SW, Lee YA, Nah SS, Suh CH, Yoo DH, Yoon BY, Bae SC;. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis. Rheumatol Int. 2017; 01. 28. [Epub]. DOI: 10.1007/s00296-016-3649-2.